For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

For people with HIV and belly fat who have high liver enzyme levels, those who lose at least 8% of their visceral fat see a bigger drop in ALT levels than those who don't lose that much fat.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

When people with HIV and belly fat lost fat from a placebo pill, their liver enzymes didn't improve, but when they lost fat from tesamorelin, their liver enzymes did improve.

In HIV patients with belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels at the start of the study.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from the drug had much bigger drops in their liver enzyme numbers compared to those who didn't lose much fat, and this difference was statistically significant.